Development and In Vitro-In Vivo Evaluation of Linezolid-Loaded Niosomal Topical Gel for Precision Therapy of Grade I Diabetic Foot Ulcers
This preclinical study demonstrates that an optimized linezolid-loaded niosomal topical gel effectively enhances drug retention, provides controlled release, and accelerates wound healing in a diabetic rat model, suggesting its potential as a targeted therapy for early-stage diabetic foot ulcers pending further clinical validation.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
When diabetes damages the nerves and blood vessels in the feet, even a small cut can turn into a stubborn, non-healing sore known as a diabetic foot ulcer. These wounds are dangerous not just because they are hard to close, but because they are prone to infection. In the early stages, before the damage reaches deep into muscle or bone, the bacteria causing trouble are often a specific type of Gram-positive organism, such as Staphylococcus aureus. Treating these infections usually requires antibiotics, but giving strong medicine through the bloodstream can cause side effects and contribute to the growing problem of drug-resistant superbugs. Scientists have long sought a way to deliver these drugs directly to the wound surface, keeping the medicine where it is needed while sparing the rest of the body. This approach relies on tiny, microscopic carriers that can hold the drug and release it slowly, combined with a gel that sticks to the skin to keep the treatment in place.
A team of researchers at Guru Ghasidas Vishwavidyalaya in India set out to build such a system using a drug called linezolid, which is effective against the Gram-positive bacteria common in these wounds. They created a special delivery vehicle called a niosome. Imagine a microscopic bubble made of a fatty shell that can trap medicine inside its core. The researchers mixed linezolid with specific ingredients, including non-ionic surfactants and cholesterol, to form these bubbles. They then used a process of hydration and sound waves to ensure the bubbles were small and uniform, trapping the drug efficiently inside. Once the bubbles were ready, they were suspended in a gel base made from common thickening agents, creating a smooth, spreadable ointment that could be applied directly to a wound.
The team first tested how well these bubbles held together and how they behaved. They found that the optimized bubbles were incredibly small, measuring about 148.6 nanometers in size, which is roughly one-thousandth the width of a human hair. They were stable, with a uniform size distribution, and held onto the drug with high efficiency, trapping about 83.6 percent of the linezolid inside. When they turned this mixture into a gel, it had the right thickness to stay on the skin without dripping, and it maintained a pH level that would not irritate the sensitive tissue around a wound. Crucially, when they tested how the drug was released, the niosomal gel did not dump all the medicine at once. Instead, it released the drug slowly over a full day, providing a steady stream of treatment rather than a sudden burst that fades quickly.
To see if this system worked better than standard treatments, the researchers compared their new gel against a plain gel containing the same amount of linezolid. They applied both to skin samples and measured how much drug stayed in the tissue versus how much passed through. The niosomal gel performed significantly better, keeping about 52.8 percent of the applied dose within the skin tissue, whereas the plain gel retained only about 26.7 percent. This meant the new formulation was much better at keeping the medicine right where the infection was, rather than letting it wash away or sink too deep into the body. The gel also maintained its ability to kill the target bacteria, including methicillin-resistant strains, proving that the process of making the bubbles did not weaken the drug.
The final test took place in a living model using diabetic rats with surgically created wounds on their backs. The researchers divided the animals into groups, treating some with nothing, some with a plain gel, some with a standard antibiotic gel, and some with their new linezolid-loaded niosomal gel. Over a period of fourteen days, the results were clear. The wounds treated with the niosomal gel healed the fastest, showing a 91.6 percent reduction in wound size by the end of the study. This was a marked improvement over the plain gel group, which saw about 78.4 percent healing. The animals treated with the new gel also developed a new layer of skin over their wounds in just 12.1 days, compared to 15.2 days for the plain gel group. Inside the healing tissue, the researchers found higher levels of collagen, the protein that gives skin its strength, and lower levels of inflammatory signals that often delay healing in diabetic patients.
Despite these promising results, the researchers are careful to define exactly where this treatment fits. They emphasize that this approach is designed only for early-stage, superficial ulcers that show signs of a specific type of bacterial infection. It is not a cure-all for deep, infected, or ischemic wounds, which require more complex medical care. The study serves as a proof of concept, showing that trapping linezolid in these microscopic bubbles and delivering it via a sticky gel can improve wound healing in a controlled setting. Before this could ever be used on people, further testing is needed to ensure it is safe for long-term use and to confirm that it works effectively in the complex environment of human diabetic feet. For now, the work stands as a significant step toward a more targeted, localized way to fight infection and help diabetic wounds heal.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.